🏥 Kesimpta share gains help lift Novartis outlook
🏥 Kesimpta share gains help lift Novartis outlook
Novartis said Thursday it now expects 5% compound annual sales growth through 2031 and core operating income above 40% by 2029, helped by stronger-than-expected commercial momentum for Kesimpta, whose peak sales forecast was raised to $8 billion from $6 billion. The company also lifted peak sales expectations for oncology drug Scemblix and Leqvio to $5 billion each, underscoring how in-market performance is supporting its medium-term outlook.
Why It Matters To Oncology
For clinicians tracking oncology drug discovery, the key signal is Scemblix: Novartis raised its peak sales forecast for the CML therapy to $5 billion from $4 billion.
The company said market share gains for Scemblix helped drive the upgraded guidance, suggesting continued confidence in its commercial durability.
Novartis also highlighted more than 35 potentially submission-enabling readouts through 2031, including over 30 high-value assets across key therapeutic areas and technology platforms.
More than 20 of those programs are already in registration, Phase III or Phase II, with at least 10 more moving into early development.
The Financials
New mid-term guidance calls for sales to grow at a 5% CAGR on a constant-currency basis through 2031.
Core operating income is expected to return to above 40% by 2029.
Kesimpta's peak sales forecast increased by $2 billion to $8 billion.
Peak revenue estimates for both Scemblix and Leqvio were raised to $5 billion from $4 billion.
What They're Saying
CEO Vas Narasimhan said Novartis expects to grow through "the largest loss-of-exclusivity impact in our history" in 2026.
He added that late-stage programs advancing through Phase III, plus a full Phase I and II pipeline, support confidence in sustaining mid-single-digit long-term growth.
Narasimhan said the upgrades were driven largely by "in-market commercial performance," citing growing market share for Kesimpta and Scemblix and strong demand for Leqvio in the U.S. and Asia.
Citi analysts said the 2031 sales guidance appeared to be about 3% above consensus, though investors may remain cautious pending additional pipeline data.
What's Next
Novartis said it now has nine de-risked, in-market assets with peak sales potential of $3 billion to $10 billion.
Investors and clinicians will be watching whether Scemblix can sustain share gains as a major oncology growth driver.
The company also flagged expected U.S. generic competition for Kisqali in the second half of 2031 as a key future consideration.
Outside oncology, Zolgensma remains under scrutiny after postmarketing reports of malignancies and product-related insertional oncogenesis involving GLI1 prompted an FDA investigation.
Reference: Novartis ups peak sales expectations for Kesimpta, Scemblix, Leqvio